Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

João Pedro Ferreira*, Timothy Collier, Andrew L Clark, Mamas A Mamas, Hans-Peter Brunner-La Rocca, Stephane Heymans, Arantxa González, Fozia Z Ahmed, Johannes Petutschnigg, Blerim Mujaj, Joe Cuthbert, Philippe Rouet, Pierpaolo Pellicori, Beatrice Mariottoni, Franco Cosmi, Frank Edelmann, Lutgarde Thijs, Jan A Staessen, Mark Hazebroek, Job VerdonschotPatrick Rossignol, Nicolas Girerd, John G Cleland, Faiez Zannad

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalEuropean Heart Journal-Cardiovascular Pharmacotherapy
Volume8
Issue number2
Early online date2 Apr 2021
DOIs
Publication statusPublished - 16 Feb 2022

Keywords

  • Cardiovascular risk
  • Hypertension
  • Spironolactone
  • Renin
  • RESISTANT HYPERTENSION
  • TASK-FORCE
  • ALDOSTERONISM
  • PREVENTION
  • MANAGEMENT
  • FIBROSIS
  • IMPACT

Cite this